All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Bookmark this article
During the 2023 Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, the GvHD Hub was pleased to speak to Yi-Bin Chen, Massachusetts General Hospital, Boston, US. We asked, Is vedolizumab effective for preventing lower gastrointestinal (GI) acute graft-versus-host disease (aGvHD)?
Is vedolizumab effective for preventing lower GI acute GvHD?
Chen begins by summarizing the justifications, methods, and data from the phase III randomized, double blind, placebo-controlled GRAPHITE trial of vedolizumab. GRAPHITE was a prospective large cohort trial with a primary endpoint of lower GI aGvHD-free survival by Day 180. Chen explains the trials clinical significance, highlighting overall survival, relapse free survival, and safety.
Chen concludes by discussing the impact of current clinical trials on future treatment and prevention strategies for GvHD, as well as the impact of new interventions on patient populations.
GvHD prophylaxis with abatacept in mismatched unrelated donor HCT
Addition of abatacept to standard immunoprophylaxis can improve GvHD related transplant outcomes in mismatched unrelated donor HCT recipients.
Yi-Bin Chen | ASH 2018 | Vedolizumab plus standard of care for GvHD prophylaxis
Yi-Bin Chen Massachusetts General Hospital, Boston, US
Subscribe to get the best content related to GvHD delivered to your inbox